Why the study?
Cardiovascular disease is the leading cause of US maternal mortality, yet contraception can prevent mortality and morbidity from unplanned pregnancy in patients with congenital or acquired heart disease.
What are the safe and effective contraceptive methods for patients with underlying congenital or acquired heart disease based on the 2024 US Medical Eligibility Criteria?
What are the safe and effective contraceptive methods for patients with underlying congenital or acquired heart disease based on the 2024 US Medical Eligibility Criteria?
This review highlights that intrauterine devices, implants, and progestin-only contraceptives are safe and highly effective for most patients with cardiac disease, while estrogen-containing methods carry higher risks.
Answers are grounded in this paper and cite their sources.
May guide contraceptive counseling in cardiac patients; leaves open need for prospective validation of estrogen risks.
Cardiovascular disease is the leading cause of maternal mortality in the United States, with the majority of deaths stemming from preventable causes. Contraception is one of the tools that can be utilized to prevent mortality and morbidity associated with unplanned pregnancy in patients with underlying congenital or acquired heart disease. There are a wide range of contraceptive methods available. While some methods, especially those containing estrogen, may be associated with increased risks in certain cardiac disease states, intrauterine devices, implants, and progestin-only methods may be safely used by the vast majority of patients with cardiac disease. Furthermore, intrauterine devices and implants are the most effective reversible contraceptive methods available. This review provides a summary of the US Centers for Disease Control and Prevention 2024 Medical Eligibility Criteria for Contraceptive Use as it applies to cardiac disease states. This review emphasizes the importance of contraceptive counseling and aims to familiarize the reader with the various forms of contraception available to patients, as well as the risks and benefits of each method in patients with different types of cardiac disease.
No takes yet. Share an insight, caveat, or question.
Shapero et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: